Epilepsy Talk

Increased Birth Defect Risks in Two FDA-Approved Epilepsy Medications | October 20, 2011

Two epilepsy drugs – Lamictal and Keppra – which are currently listed in category C may be dangerous to a fetus and should be listed in category D, according to new data. The difference between the categories is that D shows evidence of risk, but the benefits outweigh the risks. While category C is indicated for drugs that have shown to be harmful in animal studies…

http://central-pennsylvania.injuryboard.com/fda-and-prescription-drugs/increased-birth-defect-risks-in-two-fdaapproved-epilepsy-medications.aspx?googleid=295210

Posted in Epilepsy, Medication Issues, News, Research
Tags: , , , , ,

2 Comments »

  1. How did or do they determine that “possible” temporary benefits, out weigh permenant risks?

    Like

    Comment by mkfarnam — October 21, 2011 @ 1:24 AM

    Reply

  2. Linguistics!

    Like

    Comment by Phylis Feiner Johnson — October 21, 2011 @ 1:44 PM

    Reply

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

    About the author

    Phylis Feiner Johnson

    Phylis Feiner Johnson

    I've been a professional copywriter for over 35 years. I also had epilepsy for decades. My mission is advocacy; to increase education, awareness and funding for epilepsy research. Together, we can make a huge difference. If not changing the world, at least helping each other, with wisdom, compassion and sharing.

    View Full Profile →

    Enter your email address to follow this blog and receive free notifications of new posts by email.

    Join 3,265 other subscribers
    Follow Epilepsy Talk on WordPress.com
%d bloggers like this: